OverviewSuggest Edit
Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
| Type | Public | |
| Founded | 2012 | |
| HQ | Redwood City, US | Map |
| Website | allakos.com |
Recent NewsAll News
- ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed
- ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. - ALLK
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud
Key People/Management at Allakos
Robert Alexander
Chief Executive Officer, Director
Dan Janney
Chairman
Robert Andreatta
Director
Mark Asbury
Chief Legal Officer, General Counsel
Paul Walker
Director
Simon Greenwood
Chief Business Officer
Allakos Office Locations
Allakos has an office in Redwood City
Redwood City, US (HQ)
975 Island Dr #201
Allakos Financials and Metrics
Allakos Revenue
| USD | |
|---|---|
Net income (Q1, 2020) | (27.8m) |
EBIT (Q1, 2020) | (29.9m) |
Market capitalization (29-May-2020) | 3.2b |
Closing stock price (29-May-2020) | 65.0 |
Cash (31-Mar-2020) | 135.9m |
EV | 3.0b |
Allakos's current market capitalization is $3.2 b.
Annual
Annual
Annual
| USD | Y, 2020 |
|---|---|
EV/EBIT | -101.8 x |
EV/CFO | -163.6 x |
Financial Leverage | 1 x |
Allakos Online and Social Media Presence
Allakos's Trends
Allakos News and Updates
March 12, 2020
ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK
NEW YORK, March 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is first to file a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the "Class...
March 12, 2020
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed
SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. Class...
January 18, 2020
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. - ALLK
NEW YORK, Jan. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
December 20, 2019
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud
SAN FRANCISCO, Dec. 19, 2019 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The firm is investigating Allakos...
December 04, 2019
U.S. biotech firm Allakos exploring options, including sale - Bloomberg
U.S. biotech company Allakos Inc
is considering strategic options that include a potential sale,
Bloomberg reported on Wednesday, citing people familiar with the
matter.
December 04, 2019
Allakos stock jumps in afternoon trading
Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high. Sources told Bloomberg that the Redwood, Calif.-based biopharmaceutical company, which went public in August, is considering a sale. Allakos is in the early stages of developing treatments for eosinophilic gastritis and alle…
Allakos Blogs
March 24, 2020
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
Content Import
Tue, 03/24/2020 - 16:01
Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
March 24, 2020 at 4:01 PM EDT
This release is a backfill from a News Wire
…
February 25, 2020
Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Content Import
Tue, 02/25/2020 - 16:02
Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
February 25, 2020 at 4:01 PM EST
…
February 24, 2020
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
REDWOOD CITY, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results
November 12, 2019
Allakos Reports Third Quarter 2019 Financial Results
REDWOOD CITY, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported financial results for the third quarter ended September 30, 2019.
October 28, 2019
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
Content Import
Mon, 10/28/2019 - 09:01
Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointe…
August 05, 2019
Allakos Reports Second Quarter 2019 Financial Results
Allakos Reports Second Quarter 2019 Financial Results
Content Import
Mon, 08/05/2019 - 07:15
Allakos Reports Second Quarter 2019 Financial Results
August 5, 2019 at 7:15 AM EDT
This release is a backfill from a News Wire
Earnings
REDW…
Allakos Frequently Asked Questions
When was Allakos founded?
Allakos was founded in 2012.
Who are Allakos key executives?
Allakos's key executives are Robert Alexander, Dan Janney and Robert Andreatta.
How many employees does Allakos have?
Allakos has 90 employees.
Who are Allakos competitors?
Competitors of Allakos include CinCor Pharma, Sosei Heptares and Vyriad.
Where is Allakos headquarters?
Allakos headquarters is located at 975 Island Dr #201, Redwood City.
Where are Allakos offices?
Allakos has an office in Redwood City.
How many offices does Allakos have?
Allakos has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies